Company Encyclopedia
View More
name
Viridian Therapeutics
VRDN.US
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. The company’s product pipeline includes veligrotug, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R monoclonal antibodies targeting IGF-1R and engineered of half-life extension technology, which is in Phase 3 clinical trial for the treatment of TED. It also develops portfolio of engineered anti-neonatal Fc receptor inhibitors, such as VRDN-006 and VRDN-008 for autoimmune disease.
1.875 T
VRDN.USMarket value -Rank by Market Cap -/-

Financial Score

21/11/2025 Update
C
BiotechnologyIndustry
Industry Ranking82/394
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-58.92%E
    • Profit Margin-426.58%E
    • Gross Margin-22.23%E
  • Growth ScoreB
    • Revenue YoY23340.07%A
    • Net Profit YoY-65.50%D
    • Total Assets YoY-25.23%E
    • Net Assets YoY-28.91%E
  • Cash ScoreB
    • Cash Flow Margin-28.86%D
    • OCF YoY23340.07%A
  • Operating ScoreE
    • Turnover0.1E
  • Debt ScoreA
    • Gearing Ratio12.85%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Viridian Therapeutics (NASDAQ:VRDN) Hits New 12-Month High on Earnings Beat

    Viridian Therapeutics (NASDAQ:VRDN) reached a new 12-month high of $28.59 after reporting better-than-expected earnings, with an EPS of ($0.34) against a consensus estimate of ($0.82). The stock closed at $28.2170, up from $24.42. Analysts have set new price targets, with Oppenheimer raising theirs to $36.00 and BTIG maintaining a $61.00 target. Institutional investors have also increased their stakes significantly. The company focuses on developing treatments for serious diseases, with products in clinical trials for thyroid eye disease.

    Market Beat·
    US
    VRDN
    +2.75%
    Market Beat·
    US
    VRDN
    +2.75%

    Viridian Therapeutics Grants Stock Options to New Employees

    Viridian Therapeutics Inc. has granted non-qualified stock options for 88,300 shares to four new employees. The exercise price is set at the closing price on the grant date, November 3, 2025. The options will vest over four years, with 25% vesting on the first anniversary and the remainder in 36 monthly installments, contingent on continued employment.

    Reuters·
    US
    VRDN
    +2.75%
    Reuters·
    US
    VRDN
    +2.75%

    Viridian Therapeutics Advances Toward Profitability with Strategic Moves

    Viridian Therapeutics, Inc. (VRDN) reported its Q3 earnings, highlighting significant advancements towards profitability. The company submitted a Biologics License Application for veligrotug to the FDA and secured a financing package of up to $889 million. As of October 31, 2025, Viridian holds approximately $887.9 million in cash, with R&D expenses at $86.3 million and a net loss of $34.6 million for the quarter. The company aims for a U.S. commercial launch of veligrotug in mid-2026 and remains optimistic about achieving profitability through its strategic initiatives and potential revenues from its treatments.

    Tip Ranks·
    US
    VRDN
    +2.75%
    Tip Ranks·
    US
    VRDN
    +2.75%

    Viridian Therapeutics: Promising Future with Strategic Trials and Financial Stability

    Viridian Therapeutics is viewed positively by analyst Serge Belanger, who has issued a Buy rating due to the company's promising future. The completion of enrollment for Phase 3 REVEAL trials for drug VRDN-003 is a significant milestone, with results expected in 2026. The company has also filed a Biologics License Application for its drug veli, with FDA acceptance anticipated soon. Financially, Viridian has secured up to $889 million, enhancing its stability for future developments. Wedbush also maintains a Buy rating with a $42 price target.

    Tip Ranks·
    US
    VRDN
    +2.75%
    Tip Ranks·
    US
    VRDN
    +2.75%

    H.C. Wainwright Keeps Their Buy Rating on Viridian Therapeutics (VRDN)

    Tsao covers the Healthcare sector, focusing on stocks such as Protagonist Therapeutics, Cabaletta Bio, and Hansa Biopharma AB. According to TipRanks, Tsao has an average return of 22.0% and a 53.85% success rate on recommended stocks. In addition to H.C. Wainwright, Viridian Therapeutics also received a Buy from Wedbush’s Laura Chico in a report issued today. However, on October 23, TR | OpenAI – 4o reiterated a Hold rating on Viridian Therapeutics (NASDAQ: VRDN).

    Tip Ranks·
    US
    VRDN
    +2.75%
    Tip Ranks·
    US
    VRDN
    +2.75%